Do Statins Reduce Inflammation? Why They Lower CRP, Not Just Cholesterol

Why a cholesterol drug shows up in an inflammation story

Clogged arteries are not only a plumbing problem. Chronic, low-level inflammation is a hallmark of the artery disease behind heart attacks and strokes.1 One way to measure it is CRP, short for C-reactive protein, a blood marker of inflammation.1

Statins were built to lower LDL, the "bad" cholesterol. But they lower CRP too.2 That raised a question worth testing. Was some of the benefit coming from calming inflammation?

Do statins reduce inflammation in the body?

Yes, and the evidence is large. A 2024 meta-analysis pooled 53 randomized trials with more than 170,000 people, each comparing a cholesterol drug with a placebo.1 Statins lowered CRP by about 0.65 mg per liter.1 Three other drug types lowered it less, and two did not lower it at all.1

Statins reduce CRP independently of how much they lower LDL cholesterol.From a 2024 meta-analysis in Cardiovasc Res

The detail that matters most: the CRP drop did not line up with the LDL drop.1 The authors concluded that statins reduce CRP independently of LDL.1 That is about as close as the data gets to calling statins anti-inflammatory in their own right.

The finding holds in different groups. A 2023 meta-analysis of 35 trials with 26,521 people without heart disease found lower CRP on both main types of statin.5 A pooled analysis of 113 trials in people with metabolic syndrome found lower CRP, IL-6 (interleukin-6, another inflammation signal), TNF-alpha and IL-1, though those trials varied a lot from one another.6

Here is the honest caveat. In the people without heart disease, statins did not clearly change IL-6, TNF-alpha or six other markers.5 CRP is the marker that moves most reliably.

Does lowering CRP protect the heart?

In 2005, researchers followed 3,745 people with acute coronary syndromes (sudden heart problems such as heart attacks) who were on one of two statins.8 People whose LDL fell below 70 mg per deciliter did better.8 But people whose CRP fell below 2 mg per liter did better by almost exactly the same amount, at every level of LDL.8 Those who hit both targets did best.8

Then came JUPITER in 2008. It enrolled 17,802 healthy adults whose LDL was not high but whose CRP was 2 mg per liter or higher, and gave them rosuvastatin 20 mg a day or a placebo.2 The drug lowered LDL by 50% and CRP by 37%.2 The trial was stopped after a median of 1.9 years, with major heart events down 44% (a hazard ratio of 0.56).2 Deaths from any cause fell too, though the statin group had more doctor-reported diabetes.2

So people with "normal" cholesterol but high CRP could still benefit.2 What JUPITER could not prove is that the CRP drop did the work, because the drug lowered both numbers at once.

The inflammation left over

A different trial got closer to that answer. CANTOS, published in 2017, tested canakinumab, a drug that blocks an inflammation signal called IL-1 beta, in 10,061 people who had had a heart attack and still had a CRP of 2 mg per liter or higher.9 It did not lower cholesterol, yet at the 150 mg dose it led to fewer repeat heart events than placebo.9 It also brought more fatal infections and no change in deaths from any cause.9

That matters for statin users because of what researchers call residual inflammatory risk: the inflammation still there after cholesterol is under control. A 2023 analysis of 31,245 people already taking statins found that those in the top quarter for CRP had about 31% more major heart events than those in the bottom quarter.3 Their risk of dying from heart disease was more than double.3 LDL, by contrast, was a much weaker predictor in these statin users.3

A 2020 meta-analysis of 14 trials with 133,109 people agreed. Stronger cholesterol lowering cut heart events but did not push CRP down further, leaving some inflammatory risk behind.4

So statins do two jobs at once. For some people, the second job is not finished.

Do statins cause inflammation, or muscle pain?

Usually people mean muscle aches. The best data comes from 19 large double-blind trials with 123,940 people, where nobody knew who was on the real drug.10 Muscle pain or weakness was reported by 27.1% of people on a statin. On placebo it was 26.6%.10 More than 90% of muscle complaints in the statin groups were not caused by the statin.10 The small real excess was mostly mild, showed up mainly in the first year, and was much smaller than the heart benefit.10

The bottom line

A drug built for cholesterol, a CRP drop in 53 trials, JUPITER stopped early, and statin users whose leftover inflammation still predicts trouble. Put together, the picture is clear. Statins do reduce inflammation, and CRP is where you can see it. They just don't erase it. For anyone who takes one, the CRP number is worth knowing too.